Presidio Property Trust, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
SQFTW$0.01+3.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Real estate assets and lease intangibles: | ||
| Land | $16,390,250 | $15,983,323 |
| Buildings and improvements | 101,878,107 | 102,862,977 |
| Tenant improvements | 17,645,103 | 16,488,066 |
| Lease intangibles | 3,467,798 | 3,776,654 |
| Real estate assets and lease intangibles held for investment, cost | 139,381,258 | 139,111,020 |
| Accumulated depreciation and amortization | (37,536,809) | (33,700,262) |
| Real estate assets and lease intangibles held for investment, net | 101,844,449 | 105,410,758 |
| Real estate assets held for sale, net | 6,805,255 | 22,185,742 |
| Real estate assets, net | 108,649,704 | 127,596,500 |
| Other assets: | ||
| Cash, cash equivalents and restricted cash | 7,422,359 | 8,036,496 |
| Deferred leasing costs, net | 1,340,853 | 1,666,135 |
| Goodwill | 1,317,000 | 1,389,000 |
| Investment in Conduit Pharmaceuticals marketable securities (see Notes 2 & 9) | 3,900 | 206,177 |
| Deferred tax asset | 223,388 | 298,645 |
| Other assets, net (see Note 6) | 3,095,670 | 3,376,697 |
| Total other assets | 13,403,170 | 14,973,150 |
| TOTAL ASSETS (1) | $122,052,874 | $142,569,650 |
| LIABILITIES AND EQUITY | ||
| Liabilities: | ||
| Mortgage notes payable, net | $81,936,586 | $80,977,448 |
| Mortgage notes payable related to properties held for sale, net | 10,137,781 | 21,116,646 |
| Mortgage notes payable, total net | 92,074,367 | 102,094,094 |
| Accounts payable and accrued liabilities | 3,302,187 | 3,290,170 |
| Accrued real estate taxes | 1,785,029 | 1,972,477 |
| Dividends payable | 190,220 | 194,784 |
| Lease liability, net | 40,108 | 64,345 |
| Below-market leases, net | 3,316 | 8,625 |
| Total liabilities | 97,395,227 | 107,624,495 |
| Commitments and contingencies (see Note 10) | ||
| Equity: | ||
| Series D Preferred Stock, $0.01 par value per share; 1,000,000 shares authorized; 973,736 shares issued and outstanding (liquidation preference $25.00 per share) as of December 31, 2025 and 997,082 shares issued and outstanding as of December 31, 2024 | 9,737 | 9,971 |
| Series A Common Stock, $0.01 par value per share, shares authorized: 100,000,000; 1,313,832 shares and 1,283,432 shares were issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 13,142 | 128,343 |
| Additional paid-in capital | 186,762,388 | 185,770,842 |
| Dividends and accumulated losses | (169,945,302) | (159,374,010) |
| Total stockholders' equity before noncontrolling interest | 16,839,965 | 26,535,146 |
| Noncontrolling interest | 7,817,682 | 8,410,009 |
| Total equity | 24,657,647 | 34,945,155 |
| TOTAL LIABILITIES AND EQUITY | $122,052,874 | $142,569,650 |
(1) As of December 31, 2025 and 2024, includes approximately $8.6 million and $11.4 million, respectively, of assets related to consolidated variable interest entities that can be used only to settle obligations of the consolidated variable interest entities.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.